Home
Conditions
Refractory Malignant Solid Neoplasm

Clinical trial condition

Refractory Malignant Solid Neoplasm

Explore clinical trials studying Refractory Malignant Solid Neoplasm. Study availability and eligibility vary by location and protocol.

91 public trials 12 recruiting studies

Refine in advanced search Browse all conditions

Refractory Malignant Solid Neoplasm trial results

Active, Not Recruiting

Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors

NCT02079740

Conditions: Metastatic Malignant Solid Neoplasm, Neoplasm Metastasis, Neoplasms, +5 more
Locations: Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States

Dana-Farber Cancer Institute Boston, Massachusetts, United States

View Trial Details

Active, Not Recruiting

Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)

NCT06400238

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +19 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Active, Not Recruiting

Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)

NCT06357988

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +20 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Active, Not Recruiting

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)

NCT06360575

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +19 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Active, Not Recruiting

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

NCT06303167

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +22 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Active, Not Recruiting

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)

NCT04439149

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +22 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Active, Not Recruiting

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P)

NCT04439188

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +22 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Active, Not Recruiting

Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)

NCT06400225

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +19 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Active, Not Recruiting

Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L)

NCT06385496

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +19 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Active, Not Recruiting

Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)

NCT06390865

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +19 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Refractory Malignant Solid Neoplasm

Refractory Malignant Solid Neoplasm trial results

Related conditions